Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre, open-label, randomised, phase 2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer (all hormonal status tumour except triple negative tumour) and who relapsed after a first line chemotherapy.

Next Previous
X
Search
Trial Profile

A prospective, multicentre, open-label, randomised, phase 2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer (all hormonal status tumour except triple negative tumour) and who relapsed after a first line chemotherapy.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masitinib (Primary) ; Capecitabine; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AB Science

    • Most Recent Events

    • 04 Nov 2019 This trial has been withdrawn prior to enrolment in Slovakia, according to European Clinical Trials Database.
    • 18 May 2019 This trial has been completed in Spain (On-2016-05-05), according to European Clinical Trials Database.
    • 21 Sep 2017 This trial has been suspended in Slovakia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top